Veracyte Stock Price, News & Analysis (NASDAQ:VCYT)

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte Inc (NASDAQ:VCYT) issued its quarterly earnings data on Tuesday, July, 30th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. The biotechnology company earned $30.14 million during the quarter, compared to the consensus estimate of $29.20 million. Veracyte had a negative net margin of 11.01% and a negative return on equity of 10.26%. View Veracyte's Earnings History.

Veracyte is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Veracyte.

Veracyte will be holding an earnings conference call on Tuesday, October 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Veracyte updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $119-122 million, compared to the consensus revenue estimate of $119.33 million.

5 Wall Street analysts have issued 12-month price targets for Veracyte's shares. Their forecasts range from $12.30 to $35.00. On average, they expect Veracyte's stock price to reach $24.58 in the next year. This suggests that the stock has a possible downside of 3.6%. View Analyst Price Targets for Veracyte.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.

News articles about VCYT stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Veracyte earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Veracyte.

Veracyte saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,570,000 shares, an increase of 127.4% from the August 30th total of 2,010,000 shares. Based on an average trading volume of 633,600 shares, the days-to-cover ratio is presently 7.2 days. Approximately 10.4% of the shares of the stock are short sold. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Biocept (BIOC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), Advanced Micro Devices (AMD), Netflix (NFLX), AbbVie (ABBV), Alibaba Group (BABA), Chipotle Mexican Grill (CMG) and Exelixis (EXEL).

Veracyte's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (2.49%), First Hawaiian Bank (0.04%) and Bowling Portfolio Management LLC (0.03%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu and John Walter Hanna Jr. View Institutional Ownership Trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC and First Hawaiian Bank. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu and John Walter Hanna Jr. View Insider Buying and Selling for Veracyte.

VCYT stock was purchased by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC. View Insider Buying and Selling for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $25.48.

Veracyte has a market capitalization of $1.23 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.

The official website for Veracyte is http://www.veracyte.com/.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]